reports
Kering and L’oréal Forge an Alliance in Beauty and Wellness
Kering and L’oréal Forge an Alliance in Beauty and Wellness PRESS RELEASE KERING AND L’ORÉAL FORGE AN ALLIANCE IN BEAUTY AND WELLNESS Paris and Clichy, France. October 19, 2025 – Kering and L’Oréal announced today that they are entering a long-term strategic partnership in luxury beauty and wellness. This binding agreement encompasses the acquisition of the House of Creed by L’Oréal, the beauty and fragrance licenses of iconic Houses of Kering and an exclusive venture to explore business opportunities in the field of wellness and longevity. Building on the success of Yves Saint L...
Kering et L'Oréal scellent une alliance dans le domaine de la beauté e...
Kering et L'Oréal scellent une alliance dans le domaine de la beauté et du bien-être COMMUNIQUÉ DE PRESSE KERING ET L'ORÉAL SCELLENT UNE ALLIANCE DANS LE DOMAINE DE LA BEAUTÉ ET DU BIEN-ÊTRE Paris et Clichy, France. 19 octobre 2025. Kering et L’Oréal ont annoncé aujourd’hui la conclusion d’un partenariat stratégique de long terme dans la beauté et le bien-être de luxe. Cet accord ferme couvre l’acquisition de la Maison Creed par L’Oréal, la signature des licences de beauté et de fragrances de Maisons emblématiques de Kering, et une coentreprise exclusive visant à explorer des opp...
Kering and L’Oréal forge an alliance in beauty and wellness
Kering and L’Oréal forge an alliance in beauty and wellness PRESS RELEASE KERING AND L’ORÉAL FORGE AN ALLIANCE IN BEAUTY AND WELLNESS Paris and Clichy, France. October 19, 2025 – Kering and L’Oréal announced today that they are entering a long-term strategic partnership in luxury beauty and wellness. This binding agreement encompasses the acquisition of the House of Creed by L’Oréal, the beauty and fragrance licenses of iconic Houses of Kering and an exclusive venture to explore business opportunities in the field of wellness and longevity. Building on the success of Yves Saint Laurent...
Kering et L'Oréal scellent une alliance dans le domaine de la beauté e...
Kering et L'Oréal scellent une alliance dans le domaine de la beauté et du bien-être COMMUNIQUÉ DE PRESSE KERING ET L'ORÉAL SCELLENT UNE ALLIANCE DANS LE DOMAINE DE LA BEAUTÉ ET DU BIEN-ÊTRE Paris et Clichy, France. 19 octobre 2025. Kering et L’Oréal ont annoncé aujourd’hui la conclusion d’un partenariat stratégique de long terme dans la beauté et le bien-être de luxe. Cet accord ferme couvre l’acquisition de la Maison Creed par L’Oréal, la signature des licences de beauté et de fragrances de Maisons emblématiques de Kering, et une coentreprise exclusive visant à explorer des opportunité...
- ABGSC Financials Research
- Magnus Andersson
- Patrik Brattelius
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- ABGSC Online Gaming Research
- Nikola Kalanoski
- Simon Jönsson
- ABGSC Capital Goods Research
- Anders Idborg
- Karl Bokvist
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Oscar Lindquist
- ABGSC Healthcare Research
- Morten Larsen
- ABGSC Construct. & Real Estate Research
- Fredrik Stensved
- Oscar Lindquist
Vantage Drilling International Ltd. – Announcement of Contract Termina...
Vantage Drilling International Ltd. – Announcement of Contract Termination Dubai, Oct. 19, 2025 (GLOBE NEWSWIRE) -- Vantage Drilling International Ltd. (the "Company”) announces the immediate termination of the contract for the Platinum Explorer for its approximately 260-day campaign. The termination is due to changes in economic sanctions applicable to the campaign, rendering the contract execution unlawful and therefore subject to termination. This information has been submitted pursuant to Section 5-12 of the Norwegian Securities Trading Act and MAR Article 17. The information was su...
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubi...
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress Median progression free survival (PFS) has not been reached in the cohort of patients with salivary gland cancer with PFS follow up suggesting a more than doubling of the benchmark PFS and a disease control rate of 91% No maximum tolerated dose reached despite dosing up to 385 mg/m² (approximately 4x conventional doxorubicin dose) with no severe cardiac toxicity observed even at cumulative doses up to 550 mg/m² LONDON and PHILAD...
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial o...
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU) SOUTH SAN FRANCISCO, Calif., Oct. 19, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that the Company plans to report topline data from the Phase 2 clinical trial of RPT904 (JYB1904) in patients with Chronic Spontaneous Urticaria (CSU) conducted ...
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the...
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the European Society for Medical Oncology (ESMO) Congress 2025 being held in Berlin (Poster 1644P). The analysis of acral melanoma patients from the IGNYTE clinical...
- ABGSC Energy Research
- John Olaisen
- Lars Trongaard Brattli
- Njål Kleiven
- Oliver Dunvold
- Jonathan Moreland
VIRC VIRCO MANUFACTURING CORP.
THFF FIRST FINANCIAL CORP. (INDIANA)
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
FDS FACTSET RESEARCH SYSTEMS INC.
CAPL CROSSAMERICA PARTNERS LP
CALM CAL-MAINE FOODS INC.
CAG CONAGRA BRANDS INC.
ANGO ANGIODYNAMICS INC.
ASA ASA
ADC AGREE REALTY CORPORATION
RIGN TRANSOCEAN LTD.
RVP RETRACTABLE TECHNOLOGIES INC.
TRT TRIO TECH INTERNATIONAL
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
AMBC AMBAC FINANCIAL GROUP INC.
GWRS GLOBAL WATER RESOURCES
BRT BRT APARTMENTS
ZIVO ZIVO BIOSCIENCE
CPSH INC.
FUND CPS TECHNOLOGIES
FGBI ROYCE FOCUS TRUST
STRO INC.
SAVA FIRST GUARANTY BANCSHARES
DX SUTRO BIOPHARMA
PNTG CASSAVA SCIENCES
PCB DYNEX CAPITAL INC.
WWR PENNANT GROUP
ACET PACIFIC CITY FINANCIAL CORP
ALTM WESTWATER RESOURCES
CGEM ADICET BIO INC
OPEN ALTUS MIDSTREAM COMPANY (A)
GGZ CULLINAN ONCOLOGY INC
IMRX OPENDOOR TECHNOLOGIES INC.
REFI GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
PEPG IMMUNEERING CORP
VANI CHICAGO ATLANTIC REAL ESTATE FINANCE INC
UAMY PEPGEN INC
SOC VIVANI MEDICAL INC
LAW U S ANTIMONY CORP
MRAI SABLE OFFSHORE CORP
HYMC CS DISCO INC
SABS MARPAI
INC.
HYCROFT MINING HOLDING CORPORATION
BIG CYPRESS ACQUISITION CORP.
Sify Technologies to announce Financial Results for Second Quarter FY ...
Sify Technologies to announce Financial Results for Second Quarter FY 2025-26 on Saturday, October 25, 2025 CHENNAI, India, Oct. 18, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: SIFY), India’s leading Digital ICT solutions provider with global service capabilities spanning Data Center, Cloud, Networks, Security and Digital services, today announced that it will report its unaudited IFRS financial results for the second quarter ended September 30, 2025 on Saturday, October 25, 2025 before the market opens. The following Monday, October 27, 2025, Sify will host a conference call at 8:30 AM ET with ...
Nasdaq Halts Etoiles Capital Group Co., Ltd.
Nasdaq Halts Etoiles Capital Group Co., Ltd. NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Etoiles Capital Group Co., Ltd. (Nasdaq: EFTY) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in EFTY from 04:00:00 on October 6, 2025 to 23:59:00 on October 17, 2025. The last sale price of the company’s ordinary shares was $15.02. More information about the SEC’s order can be found at . Trading will remain halted until Etoiles Capital...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.